局限期软组织肉瘤新辅助治疗的研究进展OA
Research progress on neoadjuvant therapy for localized soft tissue sarcoma
软组织肉瘤是一类恶性程度高、亚型繁多的肿瘤.目前,手术切除仍是局限期软组织肉瘤的主要治疗方式.然而,对于局限期高危患者,单纯手术往往伴随较高的局部复发与远处转移风险,严重影响其生存质量和预后.近年来,术前新辅助治疗迅速发展,为这部分患者提供了新的治疗选择.该文旨在综述软组织肉瘤新辅助治疗的研究现状、临床疗效及当前面临的挑战,以期为改善局限期软组织肉瘤患者的治疗效果提供新策略.
Soft tissue sarcoma is a type of tumor with high malignancy and a wide range of subtypes.Currently,surgical resection remains the primary treatment for localized soft tissue sarcoma.However,for high-risk patients with localized disease,surgery alone often carries a high risk of local recurrence and distant metastasis,significantly affecting their quality of life and prognosis.In recent years,the rapid development of preoperative neoadjuvant therapy has provided new treatment options for these patients.This article aims to review the current research status,clinical efficacy,and current challenges of neoadjuvant therapy for soft tis-sue sarcoma,with the hope of providing new strategies to improve the treatment outcomes for patients with localized soft tissue sarcoma.
毛开金;向姝;周清华
重庆大学附属肿瘤医院放射治疗中心,重庆 400030重庆武警总队医院消化科,重庆 400061彭水苗族土家族自治县人民医院放射治疗中心,重庆 409600
医药卫生
软组织肉瘤新辅助治疗手术放疗化疗
soft-tissue sarcomaneoadjuvant therapysurgeryradiotherapychemotherapy
《重庆医学》 2026 (3)
681-685,690,6
重庆市卫生健康委医学科研项目(2025WSJK038).
评论